BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
BCRX has been the subject of a number of other reports. FBR & Co reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Thursday, September 8th. JMP Securities lowered BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Friday, August 5th. Piper Jaffray Cos. upgraded BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $5.00 to $8.00 in a report on Friday, August 12th. Finally, Jefferies Group lifted their target price on BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a report on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 1.09% during trading on Tuesday, reaching $4.53. The company had a trading volume of 502,881 shares. The firm’s market capitalization is $333.86 million. The company’s 50-day moving average is $4.43 and its 200 day moving average is $3.50. BioCryst Pharmaceuticals has a 52 week low of $1.63 and a 52 week high of $12.54.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.04. The firm earned $4.80 million during the quarter, compared to analyst estimates of $3.92 million. BioCryst Pharmaceuticals had a negative return on equity of 187.98% and a negative net margin of 285.24%. BioCryst Pharmaceuticals’s revenue was down 81.4% compared to the same quarter last year. During the same period last year, the business posted $0.06 earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals will post ($1.03) EPS for the current year.
In other news, VP Alane P. Barnes sold 8,357 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $4.27, for a total transaction of $35,684.39. Following the sale, the vice president now owns 79,377 shares in the company, valued at $338,939.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Yarlagadda S. Babu sold 30,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $4.06, for a total value of $121,800.00. Following the sale, the vice president now owns 111,428 shares in the company, valued at approximately $452,397.68. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in BioCryst Pharmaceuticals by 11.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,237,418 shares of the biotechnology company’s stock worth $3,502,000 after buying an additional 130,133 shares during the period. Royce & Associates LP bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $453,000. HBK Investments L P boosted its position in shares of BioCryst Pharmaceuticals by 152.7% in the first quarter. HBK Investments L P now owns 49,773 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 30,073 shares during the period. Amici Capital LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $283,000. Finally, Spark Investment Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 505.1% in the first quarter. Spark Investment Management LLC now owns 530,100 shares of the biotechnology company’s stock valued at $1,500,000 after buying an additional 442,500 shares during the period. Institutional investors and hedge funds own 70.34% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.